The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...

Pfizer (NYSE: PFE) stock investors are curious about the valuation and prospects for the healthcare company. *Stock prices ...

PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

In 1987, fewer than one in five American adults were obese, and by 1999, obesity was responsible for more than 300,000 excess ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...